Clinical Trials Logo

Clinical Trial Summary

The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06013241
Study type Interventional
Source Insmed Incorporated
Contact Insmed Medical Information
Phone 1-844-446-7633
Email medicalinformation@insmed.com
Status Recruiting
Phase Phase 2
Start date October 30, 2023
Completion date September 25, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06069310 - Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
Active, not recruiting NCT05553951 - Adherence in Global Airways N/A
Active, not recruiting NCT06118554 - 3D Printing to Improve Nasal Irrigation Outcome N/A
Recruiting NCT06398873 - Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP
Withdrawn NCT04158596 - Safety and Efficacy of SDX-3101 for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) N/A
Recruiting NCT05642806 - Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment Phase 4
Completed NCT04678856 - Dupilumab in CRSsNP Phase 2
Terminated NCT01676415 - Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Phase 4
Recruiting NCT05843019 - Adherence in Global Airways - Steroid Intake and Effects on Chronic Rhinosinosinutis